ENPOLYAB Trademark

Trademark Overview


On Thursday, September 16, 2021, a trademark application was filed for ENPOLYAB with the United States Patent and Trademark Office. The USPTO has given the ENPOLYAB trademark a serial number of 79325766. The federal status of this trademark filing is REGISTERED as of Tuesday, December 5, 2023. This trademark is owned by BIOTEST AG. The ENPOLYAB trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical products and medical products, namely blood for medical purposes; medical preparations, namely blood for medical purposes; pharmaceutical proteins and medical protein preparations made from human blood, blood plasma and blood serum, namely, immunoglobulin preparations, immunoglobulins and hyperimmunoglobulins, all being pharmaceutical preparations for preventing and treating of immune system related diseases and disorders, neurological diseases and disorders, cancer, infections; pharmaceutical preparations for immunology, neurology, intensive medicine, transplantation medicine, oncology, namely pharmaceutical preparations for the prevention and treatment of immune system-related diseases and disorders, neurological diseases and disorders, cancer, and infections; pharmaceutical preparations for preventing and treating viral diseases, diseases of the immune system, autoimmune diseases and oncological diseases; immunosuppressant, immunomodulatory, anti-inflammatory, antiall...
enpolyab

General Information


Serial Number79325766
Word MarkENPOLYAB
Filing DateThursday, September 16, 2021
Status700 - REGISTERED
Status DateTuesday, December 5, 2023
Registration Number7232429
Registration DateTuesday, December 5, 2023
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, September 19, 2023

Trademark Statements


Goods and ServicesPharmaceutical products and medical products, namely blood for medical purposes; medical preparations, namely blood for medical purposes; pharmaceutical proteins and medical protein preparations made from human blood, blood plasma and blood serum, namely, immunoglobulin preparations, immunoglobulins and hyperimmunoglobulins, all being pharmaceutical preparations for preventing and treating of immune system related diseases and disorders, neurological diseases and disorders, cancer, infections; pharmaceutical preparations for immunology, neurology, intensive medicine, transplantation medicine, oncology, namely pharmaceutical preparations for the prevention and treatment of immune system-related diseases and disorders, neurological diseases and disorders, cancer, and infections; pharmaceutical preparations for preventing and treating viral diseases, diseases of the immune system, autoimmune diseases and oncological diseases; immunosuppressant, immunomodulatory, anti-inflammatory, antiallergic, hyposensitizing and detoxifying or toxin-neutralizing medicines, namely pharmaceutical preparations for treatment of immune-related diseases and disorders and for treatment of allergies and for treatment of infections

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes052, 051, 005, 018, 006, 044, 046
Class Status Code6 - Active
Class Status DateTuesday, January 31, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameBIOTEST AG
Party Type30 - Original Registrant
Legal Entity Type99 - Other
AddressDE

Party NameBIOTEST AG
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressDE

Party NameBIOTEST AG
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressDE

Trademark Events


Event DateEvent Description
Tuesday, March 26, 2024FINAL DECISION TRANSACTION PROCESSED BY IB
Wednesday, March 6, 2024FINAL DISPOSITION NOTICE SENT TO IB
Tuesday, March 5, 2024FINAL DISPOSITION PROCESSED
Tuesday, March 5, 2024FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Tuesday, December 5, 2023NOTICE OF REGISTRATION CONFIRMATION EMAILED
Tuesday, December 5, 2023REGISTERED-PRINCIPAL REGISTER
Tuesday, September 19, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, September 19, 2023PUBLISHED FOR OPPOSITION
Sunday, September 17, 2023NOTIFICATION PROCESSED BY IB
Wednesday, August 30, 2023NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Wednesday, August 30, 2023NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Wednesday, August 30, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Thursday, August 17, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Thursday, August 17, 2023EXAMINER'S AMENDMENT ENTERED
Thursday, August 17, 2023NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Thursday, August 17, 2023EXAMINERS AMENDMENT E-MAILED
Thursday, August 17, 2023EXAMINERS AMENDMENT -WRITTEN
Tuesday, May 9, 2023NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Wednesday, April 19, 2023NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Wednesday, April 19, 2023NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Tuesday, January 31, 2023NOTIFICATION OF FINAL REFUSAL EMAILED
Tuesday, January 31, 2023FINAL REFUSAL E-MAILED
Tuesday, January 31, 2023FINAL REFUSAL WRITTEN
Thursday, December 29, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, December 29, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, December 29, 2022TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, July 26, 2022REFUSAL PROCESSED BY IB
Saturday, July 2, 2022NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Saturday, July 2, 2022REFUSAL PROCESSED BY MPU
Saturday, June 25, 2022NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Friday, June 24, 2022NON-FINAL ACTION WRITTEN
Tuesday, June 21, 2022ASSIGNED TO EXAMINER
Tuesday, November 23, 2021APPLICATION FILING RECEIPT MAILED
Friday, November 19, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, November 18, 2021SN ASSIGNED FOR SECT 66A APPL FROM IB